Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics

Set Alert for Generics

ATOM Coalition Seeks Partners To Create New Oncology Markets

The ATOM Coalition is seeking partners in the generics and biosimilars industry to help create new markets for cancer medicines in LLMICs.

Cancer Market Access

Waverley Weighs Its Options With High Costs, Thin Margins

Waverley is evaluating options for its generics as it looks likely to throw its all at the company’s lead product candidate in the hopes of luring a development partner or buyer.

Generic Drugs Strategy

Successful Cortrophin Gel Launch Could Drive Growth At ANI For Years To Come

The launch of ANI Pharmaceutical’s Cortrophin gel has reignited interest in the ACTH drug category, and appears set to drive growth at the company for the foreseeable future.

Sales & Earnings Rare Diseases

Eagle: ‘No Room, No Reason’ For A Generics Business, As Vasopressin Pulled

In something of a surprise, Eagle Pharmaceuticals has announced its exit from the generic vasopressin market – one year after a hard-fought and hard-won launch.

Generic Drugs Strategy

Blow For EU Tecfidera Rivals As Biogen Triumphs In Legal Battle

Developers of generic dimethyl fumarate have received a setback after a CJEU ruling in Biogen’s favor gave Tecfidera EU regulatory marketing protection until at least February 2024.

Intellectual Property Legal Issues

Amneal Continues To See Value In Complexity

With Amneal delivering what it described as a “solid” set of financials for 2022, the company has reaffirmed that it sees more value in moving increasingly into complex generics and bolstering its nascent biosimilars business.

Sales & Earnings Generic Drugs

Hitting A Moving Target: Teva’s Dethlefs Discusses US Complex Generics

With a number of US complex generic opportunities in Teva’s pipeline, the company’s executive vice president for North America commercial, Sven Dethlefs, talks to Generics Bulletin about the challenges of bringing complex products to market against a backdrop of evolving FDA requirements.

Generic Drugs Regulation

The Same But Different: Biden Budget Proposes Flexibility For Generic Drug-Device Combos, ‘Skinny Labels’

President Biden's fiscal year 2024 budget pushes new legislative changes to get generic drugs to market faster.

Generic Drugs Legislation

IGBA Seeks To Underline Value And Access

Speaking with Generics Bulletin at the IGBA’s annual conference in February, chair Jonathan Kimball explained how the association is conveying the value of generics and biosimilars to international industry stakeholders.

Generic Drugs Biosimilars
See All
UsernamePublicRestriction

Register